SkinBioTherapeutics interims – apologies for delayed update and an upgrade but I had to ponder
By Tom Winnifrith | Friday 19 March 2021
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Notwithstanding the lock-in shenanigans with Optibiotix (OPTI) discussed HERE, I am more bullish than ever. The results from Skinbiotherapeutics (SBTX) for the six months to 31 December 2020 came out on Monday. I apologise for the delayed update but I needed to ponder a while. What we read a few days ago was just excellent. Hence this upgrade.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.